27 December, 2013 - ThromboGenics has announced today that Jetrea (ocriplasmin) has received a positive Common Drug Review in Canada. ThromboGenics signed a strategic partnership in 2012 with Alcon, a division of Novartis, for the commercialization of Jetrea outside of the United States.

For more details, go to: http://www.thrombogenics.com/content/thrombogenics’-jetrea®-receives-positive-common-drug-review-canada-0